Medicare Drug Pricing Models Projected to Save Billions

Researchers analyzed the potential impact of international reference pricing on U.S. Medicare spending.

Updated on Sept. 28, 2026 in Healthcare

Isometric editorial illustration showing a glass measuring vial on a clean plinth, symbolizing pharmaceutical policy analysis. — New research projects that adopting international reference pricing for Medicare could yield billions in savings by aligning U.S. drug expenditures. AI Illustration. Upload story photo >

Live Poll

Should the federal government mandate international reference pricing for prescription drugs to lower Medicare costs?

New research suggests that implementing most-favored-nation payment models could significantly reduce federal drug expenditures. The study models how tying U.S. prices to international benchmarks would lower Medicare costs for 195 brand-name drugs.

Why it matters

The findings highlight the potential for systemic policy changes to address rising healthcare costs by aligning U.S. drug prices with lower international standards. This analysis provides a quantitative framework for evaluating future legislative efforts aimed at controlling Medicare spending.

The study analyzed 195 brand-name drugs representing $87.9 billion in Medicare spending. Projections show net spending reductions of 16.1% under the GLOBE model and 17.6% under the GUARD model.

The players

Department of Health and Human Services

This federal agency is the primary overseer of Medicare programs and manages pharmaceutical manufacturer agreements.

The details

The analysis compared U.S. spending against a reference basket of 19 countries, adjusting for gross domestic product per capita. Researchers found that potential savings would decrease significantly if manufacturers with existing federal agreements were granted exemptions.

September 28, 2026: Research findings were reported by news outlets.

Market Landscape

This research provides a comparative framework for pharmaceutical pricing that follows a pattern set by the Inflation Reduction Act's Medicare drug-price negotiation provisions. By modeling international reference pricing, the study explores how the U.S. could further shift its market position relative to global pharmaceutical benchmarks.

Future adoption of these pricing models could lead to lower out-of-pocket costs for Medicare beneficiaries by reducing the baseline prices of brand-name medications. However, the extent of any relief for consumers depends on whether federal authorities choose to implement these specific reference-based payment systems.

The takeaway

These findings suggest that aligning U.S. drug prices with international lists could generate substantial federal savings. Readers should watch for future legislative proposals that incorporate reference-basket pricing to address healthcare affordability.